Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI Model Detects Cancer at Lightning Speed through Sugar Analyses

By LabMedica International staff writers
Posted on 04 Jul 2024

Glycans, which are structures made up of sugar molecules within cells, can be analyzed using mass spectrometry. More...

This technique is particularly useful because these sugar structures can reveal the presence of various cancer types within cells. However, interpreting the data from mass spectrometry, specifically, the fragmentation patterns of glycans, requires meticulous human analysis. This detailed scrutiny can take from several hours to days per sample and is only reliably performed by a handful of highly skilled experts globally, as it involves complex, learned detective work over many years. This need for expert analysis creates a significant bottleneck in utilizing glycan analysis for applications like cancer detection, especially when numerous samples need examination. Researchers have now introduced an artificial intelligence (AI) model that enhances the ability to detect cancer through sugar molecule analysis, proving to be both quicker and more effective than the traditional semi-manual approaches.

The AI model, named Candycrunch, was trained by researchers at the University of Gothenburg (Gothenburg, Sweden) using a vast database containing over 500,000 examples of various fragmentations and associated structures of sugar molecules. This extensive training has equipped Candycrunch to accurately determine the precise structure of sugars in a sample in 90% of cases, aiming to soon match the accuracy levels seen in the sequencing of other biological sequences like DNA, RNA, and proteins. The AI model described in a scientific article published in Nature Methods automates glycan analysis and completes it in just a few seconds. Moreover, Candycrunch can identify sugar structures that are typically overlooked by human analysts due to their low concentrations. Due to its speed and precision, Candycrunch significantly speeds up the identification of glycan-based biomarkers, which are crucial for diagnosing and predicting cancer. Thus, the model holds promise in aiding researchers to discover new glycan-based biomarkers for cancer.

“We believe that glycan analyses will become a bigger part of biological and clinical research now that we have automated the biggest bottleneck,” said Daniel Bojar, Associate Senior Lecturer in Bioinformatics at the University of Gothenburg.

Related Links:
University of Gothenburg


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.